CN1255854A - 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途 - Google Patents

1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途 Download PDF

Info

Publication number
CN1255854A
CN1255854A CN98805120A CN98805120A CN1255854A CN 1255854 A CN1255854 A CN 1255854A CN 98805120 A CN98805120 A CN 98805120A CN 98805120 A CN98805120 A CN 98805120A CN 1255854 A CN1255854 A CN 1255854A
Authority
CN
China
Prior art keywords
group
formula
alkyl
compound
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98805120A
Other languages
English (en)
Chinese (zh)
Inventor
E·安吉尼
M·阿达米
R·波托雷利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
Schering Plough SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough SpA filed Critical Schering Plough SpA
Publication of CN1255854A publication Critical patent/CN1255854A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN98805120A 1997-05-21 1998-05-14 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途 Pending CN1255854A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI97A001190 1997-05-21
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie

Publications (1)

Publication Number Publication Date
CN1255854A true CN1255854A (zh) 2000-06-07

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805120A Pending CN1255854A (zh) 1997-05-21 1998-05-14 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途

Country Status (9)

Country Link
EP (1) EP0983068B1 (https=)
JP (1) JP2002502370A (https=)
CN (1) CN1255854A (https=)
AT (1) ATE209492T1 (https=)
AU (1) AU740475B2 (https=)
CA (1) CA2289847A1 (https=)
DE (1) DE69802679D1 (https=)
IT (1) IT1291372B1 (https=)
WO (1) WO1998052568A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384847C (zh) * 2000-05-26 2008-04-30 先灵公司 腺苷A2a受体拮抗剂
CN100421663C (zh) * 2001-10-15 2008-10-01 先灵公司 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂
CN111072676A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20040110826A1 (en) * 2001-09-28 2004-06-10 Noriaki Uesaka Receptor Antagonists
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2010009190A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
CA2969594A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Pde2 inhibiting organic compounds
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384847C (zh) * 2000-05-26 2008-04-30 先灵公司 腺苷A2a受体拮抗剂
CN100421663C (zh) * 2001-10-15 2008-10-01 先灵公司 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂
CN111072676A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途

Also Published As

Publication number Publication date
CA2289847A1 (en) 1998-11-26
AU740475B2 (en) 2001-11-08
DE69802679D1 (de) 2002-01-10
ITMI971190A0 (https=) 1997-05-21
EP0983068B1 (en) 2001-11-28
AU7654698A (en) 1998-12-11
IT1291372B1 (it) 1999-01-07
JP2002502370A (ja) 2002-01-22
ITMI971190A1 (it) 1998-11-21
WO1998052568A1 (en) 1998-11-26
EP0983068A1 (en) 2000-03-08
ATE209492T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
CN1255854A (zh) 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
EP2916868B1 (en) Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
NL8420316A (nl) Analgetische en ontstekingsremmende preparaten met daarin xanthinen en een werkwijze voor het toepassen daarvan.
JP2015007096A (ja) 運動障害の予防および／または治療剤
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
CN113056272A (zh) 新的喹唑啉egfr抑制剂
KR20090032083A (ko) 신장 기능이 손상된 개체의 이뇨 작용 개선 방법
JP2002518442A (ja) 偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法
US9192605B2 (en) Compositions and methods for treating parkinson's disease
WO2004096228A1 (en) Method of improved diuresis in individuals with impaired renal function
KR20180081595A (ko) 이소성 지방 축적의 치료에 사용하기 위한 a3 아데노신 수용체 리간드
JP2002543133A (ja) ロフルミラストおよびｐｄｅ−３インヒビターを含有する共力薬の組合せ物
KR20070008689A (ko) 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법
EP1736155A1 (en) Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
US20090281194A1 (en) Combinations for treating HIV-associated pain
HK1261991A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK1261991B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
WO2004096227A1 (en) Pharmaceutical compositon comprising a cathepsin s inhibitor and an opioid
JP2001520194A (ja) うつ病治療のためのモキソニジンの使用
JPWO2001098300A1 (ja) 神経変性疾患予防・治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication